Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAiLS phase 3 study of pridopidine in amyotrophic lateral sclerosis
NL-OMON61057Phase 3Recruiting
- Sponsor
- Ferrer
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of pridopidine in amyotrophic lateral sclerosis (ALS), sponsored by Ferrer. Primary endpoints: ALSFRS-R total score adjusted for mortality through Week 26 and ALSFRS-R total score adjusted for mortality through Week 48. Started May 2026; status: recruiting.
02
Drugs
pridopidine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON61057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61057.